The platelet functions in patients with ankylosing spondylitis: Anti-TNF-alpha therapy decreases the mean platelet volume and platelet mass

dc.contributor.authorYazıcı, Selma
dc.contributor.authorYazıcı, Mehmet
dc.contributor.authorErer, Burak
dc.contributor.authorErer, Betül
dc.contributor.authorÇalık, Yalkın
dc.contributor.authorBulur, Serkan
dc.contributor.authorAtaoğlu, Safinaz
dc.date.accessioned2020-04-30T23:34:00Z
dc.date.available2020-04-30T23:34:00Z
dc.date.issued2010
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionWOS: 000274880600007en_US
dc.descriptionPubMed: 20050759en_US
dc.description.abstractThe present study was designed to investigate the interaction between platelet indices (mean platelet volume (MPV), platelet count (PLC) and platelet mass (PLM)), inflammatory markers and disease activity in ankylosing spondylitis (AS) subjects. The effects of anti-TNF-alpha therapy and conventional treatment on platelet indices were also compared. We studied 68 patients with AS (group I, 46 men, age: 36.4 +/- 6.9 years) and as control group 34 age and sex-matched healty subjects. All patients received conventional therapy (CT) at the beginning (Group I). The patients were reevaluated after 3 months according to Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score. Group II consisted of 35 subjects who responded to the CT and continued to take the same therapy for 3 months additionally. Group III consisted of 33 subjects who had a high disease activity score (BASDAI > 4) after 3 months and were accepted refractory to the CT therapy. In Group III the treatment was switched to infliximab and continued for 3 months at the standard intravenous dose. Significantly higher baseline MPV, PLC and PLM was reported as compared to controls decreased by therapy (9.12 +/- 1.20 vs. 8.35 +/- 0.94 fl, p < 0.001, 340 +/- 69 vs. 251 +/- 56 (x10<SU3</SU/ mu L) p < 0.0001, 3096 +/- 736 vs. 2110 +/- 384; p < 0.0001, respectively). In the same way, they were substantially lowered by both treatments in group II and group III. PLC and PLM were positively correlated with WBC and ESR (r : 0.44; p < 0.0001, r : 0.41; p = 0.001, r : 0.52; p < 0.0001, r : 0.41; p = 0.001), respectively) in AS patients. Additionally, MPV and PLM were positively correlated with BASDAI score (r : 0.41; p < 0.001, r = 0.29; p < 0.001 respectively). We have found that increased platelet activity reduced by therapy in AS patients. Additionally, it was correlated with inflammatory markers and disease activity. According to these results, it can be suggested that both anti-TNF-alpha and conventional therapy might contribute to a decrease in the risk of cardiovascular morbidity and mortality in AS patients.</.en_US
dc.identifier.doi10.3109/09537100903470306en_US
dc.identifier.endpage131en_US
dc.identifier.issn0953-7104
dc.identifier.issn1369-1635
dc.identifier.issue2en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage126en_US
dc.identifier.urihttps://doi.org/10.3109/09537100903470306
dc.identifier.urihttps://hdl.handle.net/20.500.12684/5085
dc.identifier.volume21en_US
dc.identifier.wosWOS:000274880600007en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofPlateletsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPlatelet functionen_US
dc.subjectankylosing spondylitisen_US
dc.titleThe platelet functions in patients with ankylosing spondylitis: Anti-TNF-alpha therapy decreases the mean platelet volume and platelet massen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
5085.pdf
Boyut:
117.1 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text